Schizophrenia Archives - MPR


FDA Approves Caplyta for Schizophrenia

The Food and Drug Administration (FDA) has approved Caplyta (lumateperone; Intra-Cellular Therapies), an atypical antipsychotic, for the treatment of schizophrenia in adult patients. The approval was based on results from 2 double-blind, placebo-controlled trials (Study 1 [N=335] and Study 2 [N=450]) that evaluated the efficacy of Caplyta in patients with schizophrenia for 28 days. Findings…